Sage Therapeutics is a biopharmaceutical company focused on developing medicines for brain health disorders, particularly postpartum depression.

Sage Therapeutics

Status Trial

Sage Events

Reebok Events

Domain Not Resolving

DNSSEC

Google Maps

Cloudflare JS

CDN JS

Google Maps API

ASP.NET

Amazon Virginia Region

Microsoft

Amazon Route 53

Business Management

Barry Greene

Chief Development Officer

Jim Doherty

Senior Vice President, General Counsel

Ms. Anne Marie Cook

Vice President, Early Clinical Development

Aaron Koenig Md

Vice President of Quality

Bouwien Smits

Senior Vice President, Clinical Development

Christopher Silber

Vice President Talent Acquisition

Lee Guidetti

Senior Vice President, Discovery Research

Michael Quirk

Vice President, Global Commercialization Strategy

Ms. Leena Dalal

Vice President

Robert Lasser, MD, MBA

Robert Nelsen

Molly Huntsman

Michael Rogawski

Stephen Moss

William Muir

Mark Dershwitz

Scott Grossman

Steven Paul

Eddie Carrillo

Sr. Director, Quality

Albert J. Robichaud

Kevin Starr

Board Member, Start-Up CEO

Chris Benecchi

Chief Commercial Officer

Jeff Jonas

Anne Marie Cook

Linda Stevenson

Sr. Director, Medical Affairs, Communications and Operations

Founder & Director

Greater Boston Area Companies With More Than 50 Employees

Cambridge Biotechnology Companies

United States Companies With More Than 100 Employees (Top 10K)

Greater Boston Area Public Companies With More Than $50M in Revenue

SAGE Therapeutics is dedicated to the health and well being of patients with central nervous system (CNS) disorders. Their mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.

Biogen

Post-IPO Equity - SAGE Therapeutics

Series C - SAGE Therapeutics

Third Rock Ventures

Series B - SAGE Therapeutics

Series A - SAGE Therapeutics

Cambridge

Massachusetts

United States

North America

SAGE Therapeutics

Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE

Sage Therapeutics Axes GC After Drug-Pipeline Failures Force Cost-Cutting

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce

An oral treatment for adults with postpartum depression, administered over a 14-day period.

An injectable treatment for patients 15 years and older with postpartum depression.

A drug candidate in evaluation for acute GABA hypofunction.

A drug candidate in evaluation for NMDA hypofunction.

A drug candidate in evaluation for GABA hypofunction.

Japan

Asia

India

Russian Federation

Europe

Thailand

HTML5

Google Fonts

Vimeo

Google Analytics

jQuery

Wordpress

Modernizr

Bootstrap

Office 365

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sage Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 7:57 PM	8a24aa72
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 7:57 PM	880b5125
crunchbase trigger	general	Nov 25, 2024 9:06 AM	93f1f2a4
crunchbase profile	general	Nov 25, 2024 12:39 PM	93e0b9eb
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:21 PM	43586796
peers	general	Oct 16, 2024 7:57 PM	aac703a7
news basic	general	Oct 16, 2024 7:57 PM	3022cb61
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SAGERX

Sage Therapeutics

Last Close

7.18

14/02 21:00

Market Cap

663.81M

Beta: -

Volume Today

1.85M

Avg: -